As pharmaceutical development and manufacturing become more complex, organizations are under increasing pressure to maintain execution consistency, strengthen risk identification, and manage quality across distributed operations. Digital quality systems and AI are changing how those challenges are addressed, improving visibility across the lifecycle and changing how organizations approach decision-making, governance, and operational oversight. In an interview with Chander Badwal, Senior Director, Head of Digital Quality, Thermo Fisher Scientific Pharma Services, the discussion explores how connected quality environments are evolving within regulated Good Practice (GxP) settings and what organizations need to consider as AI capabilities continue to mature.

Contract Pharma: Digital systems are well established across the industry. As development becomes more complex and distributed, what separates organizations that sustain quality performance—and how does digital maturity factor into that differentiation?

Chander Badwal: What separates organizations today is not whether they have digital quality systems. Most do. The real difference is whether those systems continue to…